Core Viewpoint - MIRXES-B (02629.HK) has signed a memorandum of understanding with Watson Bio (300142.SZ) to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1] Group 1: Partnership Details - The memorandum of understanding is effective for two years from the date of signing [1] - The collaboration aims to leverage the complementary strengths of both companies to advance early detection and preventive medicine, aligning with their long-term goals [1] Group 2: Strategic Objectives - The partnership will create synergies by combining MIRXES's advanced RNA diagnostic technology and proprietary disease RNA database with Watson's mRNA vaccine technology and strong clinical pipeline [1] - The collaboration will also utilize MIRXES's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base in the area [1]

Core Viewpoint - MIRXES-B (02629.HK) has signed a memorandum of understanding with Watson Bio (300142.SZ) to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1] Group 1: Partnership Details - The memorandum of understanding is effective for two years from the date of signing [1] - The collaboration aims to leverage the complementary strengths of both companies to advance early detection and preventive medicine, aligning with their long-term goals [1] Group 2: Strategic Implications - This partnership signifies a significant transformation for the company, moving from early detection to prevention and precision medicine [1] - The collaboration is expected to create synergies by combining the company's advanced RNA diagnostic technology and proprietary disease RNA database with Watson's mRNA vaccine technology and strong clinical pipeline [1] Group 3: Operational Capabilities - The partnership will utilize the company's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base in the area [1] - The collaboration will also enhance distribution channels within ASEAN, integrating research and commercial deployment into a cohesive prevention and precision medicine platform [1]

Core Viewpoint - The company has entered into a memorandum of understanding with Watson Bio-Tech to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1][2] Group 1: Partnership Details - The memorandum outlines collaboration in establishing an RNA-centered research center in Singapore, integrating proprietary disease RNA databases with Watson's mRNA technology to advance RNA-based diagnostic products, vaccines, and therapeutics [1] - The partnership aims to accelerate clinical trials and regulatory approvals for existing and pipeline products in the ASEAN region [1] - A sales and distribution platform will be set up in Singapore to serve the ASEAN region and specific international markets for existing and pipeline products [1] - A supply chain will be established in Singapore to coordinate end production, quality, and commercial deployment of existing and pipeline products [1] Group 2: Strategic Value - The partnership is expected to generate significant strategic value, reinforcing the company's position as a pillar in the growing RNA diagnostics and therapeutics ecosystem in the region [2] - It will expand the company's product portfolio in early detection and prevention solutions, accelerating revenue growth [2] - The RNA-centered platform will facilitate collaboration with global institutions to seize and expand regional opportunities [2] - The collaboration is anticipated to promote cross-border joint investment and cooperation opportunities, enhance corporate visibility, deepen R&D capabilities, and contribute to the long-term development and revenue diversification of the group [2]

Core Insights - The company has signed a memorandum of understanding with Yunnan Watson Bio-Technology Co., Ltd. to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform [1][2] - The memorandum outlines a two-year collaboration period and includes joint development, clinical trials, registration, and sales and distribution [1] Group 1 - The partnership aims to leverage complementary strengths to enhance the company's position in the growing RNA diagnostics and therapeutics ecosystem in the region [2] - The collaboration will expand the company's product portfolio in early detection and prevention solutions, accelerating revenue growth [2] - The RNA-centered platform is expected to facilitate cross-border investment opportunities, enhance corporate visibility, and deepen research and development capabilities [2] Group 2 - The partnership will establish an RNA-focused research center in Singapore, integrating proprietary disease RNA databases with Watson's mRNA technology [1] - Clinical trials and regulatory approvals for existing and pipeline products will be expedited in the ASEAN region [1] - A sales and distribution platform will be set up in Singapore to serve ASEAN and specific international markets [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或依 賴該等內容而引致的任何損失承擔任何責任。 Mirxes Holding Company Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） 自願性公告 與沃森的諒解備忘錄 本公告乃由Mirxes Holding Company Limited（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，旨在知會本公司股東及潛在投資者有關本集團的最新業務 發展。 – 1 – 諒解備忘錄 進行諒解備忘錄項下合作的理由及裨益 本公司董事（「董事」）會（「董事會」）宣佈，本公司近期與雲南沃森生物技術股 份有限公司（「沃森」）訂立了一份諒解備忘錄（「諒解備忘錄」），據此，訂約方已 同意發揮各自的互補優勢，就創建以RNA為中心的預防及精準醫療平台建立戰 略合作夥伴關係，並涵蓋共同開發、臨床試驗及註冊以及銷售及分銷。諒解備 忘錄的期限自簽署日期（包括該日）起為期兩年。 有關沃森的資料 沃森成立於2001年，是中國領先的高科技生物製藥 ...

Core Viewpoint - Watson Bio's stock has experienced fluctuations, with a recent decline of 2.07% and a total market capitalization of 19.72 billion yuan, reflecting ongoing challenges in revenue and profit margins [1][2]. Financial Performance - For the period from January to September 2025, Watson Bio reported a revenue of 1.719 billion yuan, a year-on-year decrease of 19.73%, and a net profit attributable to shareholders of 163 million yuan, down 36.24% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 403 million yuan, with 47.98 million yuan distributed over the past three years [2]. Stock Market Activity - As of November 18, Watson Bio's stock price was 12.33 yuan per share, with a trading volume of 385 million yuan and a turnover rate of 1.99% [1]. - The stock has seen a year-to-date increase of 2.15%, but a decline of 3.82% over the last five trading days [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 2.75% to 114,000, while the average number of circulating shares per person increased by 2.83% to 13,643 shares [2]. - The largest circulating shareholder is E Fund's ChiNext ETF, holding 34.47 million shares, a decrease of 5.80 million shares from the previous period [2].

Core Insights - Watson Bio's stock declined by 1.25% on November 17, with a trading volume of 511 million yuan, indicating a negative market sentiment towards the company [1] - The company experienced a net financing outflow of 27.51 million yuan on the same day, with total financing and securities balance reaching 1.952 billion yuan [1][2] - For the first nine months of 2025, Watson Bio reported a revenue of 1.719 billion yuan, a year-on-year decrease of 19.73%, and a net profit of 163 million yuan, down 36.24% compared to the previous year [2] Financing and Trading Activity - On November 17, Watson Bio had a financing buy-in of 53.02 million yuan, with a current financing balance of 1.94 billion yuan, representing 9.63% of its market capitalization [1] - The financing balance is below the 50th percentile level over the past year, indicating a relatively low level of leverage [1] - In terms of securities lending, Watson Bio repaid 9,200 shares and sold 63,300 shares on November 17, with a total selling amount of approximately 796,900 yuan [1] Shareholder and Institutional Holdings - As of September 30, 2025, Watson Bio had 114,000 shareholders, a decrease of 2.75% from the previous period, while the average number of circulating shares per shareholder increased by 2.83% to 13,643 shares [2] - The top institutional shareholder, E Fund's ChiNext ETF, held 34.47 million shares, down by 5.80 million shares from the previous period [2] - Other notable institutional shareholders include Southern CSI 500 ETF and China Merchants National Bio-Medical Index A, both of which also saw a reduction in their holdings [2]

Core Viewpoint - The biopharmaceutical sector experienced a slight increase of 0.44% on November 12, with significant gains from specific stocks, while the overall market indices showed a decline [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4000.14, down 0.07% - The Shenzhen Component Index closed at 13240.62, down 0.36% [1] Group 2: Top Gainers in Biopharmaceutical Sector - BGI Innovation (300318) led the gains with a closing price of 7.20, up 20.00% with a trading volume of 651,300 shares and a transaction value of 458 million yuan - Sanyuan Gene (920344) followed with a closing price of 33.15, up 12.45% and a trading volume of 85,300 shares [1] - Other notable gainers include: - Sangfor Biopharma (688336) at 68.50, up 6.60% - Sai Sheng Pharmaceutical (300485) at 12.88, up 4.63% [1] Group 3: Market Capital Flow - The biopharmaceutical sector saw a net inflow of 325 million yuan from institutional investors, while retail investors experienced a net outflow of 317 million yuan [2] - The top stocks by net inflow from institutional investors included: - Sangfor Biopharma (688336) with a net inflow of 136 million yuan - He Yuan Biopharma (688765) with a net inflow of 108 million yuan [3]

Group 1 - Watson Bio's stock increased by 5.44%, reaching 13.17 CNY per share, with a trading volume of 588 million CNY and a turnover rate of 2.99%, resulting in a total market capitalization of 21.063 billion CNY [1] - The company, Yunnan Watson Bio-Tech Co., Ltd., was established on January 16, 2001, and listed on November 12, 2010. Its main business involves the research, production, and sales of vaccine products [1] - The revenue composition of Watson Bio includes 94.82% from self-developed vaccine products, 4.67% from intermediate products, 0.26% from other supplementary products, and 0.24% from technical services [1] Group 2 - According to data, one fund under Penghua Fund has a significant holding in Watson Bio. The Biovaccine ETF (159657) reduced its holdings by 78,600 shares in the third quarter, now holding 581,300 shares, which accounts for 5.71% of the fund's net value, ranking it as the fifth-largest holding [2] - The Biovaccine ETF (159657) was established on February 22, 2023, with a current size of 118 million CNY. Year-to-date, it has achieved a return of 10.75%, ranking 3652 out of 4216 in its category; over the past year, it has incurred a loss of 0.67%, ranking 3697 out of 3922; since inception, it has lost 29.12% [2] - The fund manager of the Biovaccine ETF is Lin Song, who has been in the position for 2 years and 136 days. The total asset size under his management is 1.777 billion CNY, with the best fund return during his tenure being 22.42% and the worst being -15.21% [2]

Core Viewpoint - Watson Bio's stock has shown fluctuations with a recent increase of 2.08%, while the company faces a decline in revenue and profit year-on-year [1][2]. Group 1: Stock Performance - As of November 11, Watson Bio's stock price reached 12.75 CNY per share, with a market capitalization of 20.39 billion CNY [1]. - Year-to-date, the stock has increased by 5.63%, with a 3.41% rise over the last five trading days and an 11.94% increase over the last 20 days [1]. - The stock has experienced a decline of 3.56% over the past 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Watson Bio reported a revenue of 1.72 billion CNY, a year-on-year decrease of 19.73% [2]. - The net profit attributable to shareholders for the same period was 163 million CNY, reflecting a year-on-year decline of 36.24% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 2.75% to 114,000, while the average number of circulating shares per person increased by 2.83% to 13,643 shares [2]. - The company has distributed a total of 403 million CNY in dividends since its A-share listing, with 47.98 million CNY distributed over the last three years [3]. - The largest circulating shareholder is E Fund's ChiNext ETF, holding 34.47 million shares, a decrease of 5.80 million shares from the previous period [3].